Sarepta Therapeutics (SRPT) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -317.4 | -594.9 | -453.7 | 316.9 | -648.0 | 125.0 | ||
| Changes by years, y/y, % | -30% | +87% | -24% | -170% | -304% | +7.4% | |||
Sarepta Therapeutics. EBITDA US GAAP, bln rub
Sarepta Therapeutics. EBITDA US GAAP, changes, %
Sarepta Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Sarepta Therapeutics (SRPT) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, bln rub | ? | -369.0 | 169.7 | -168.0 | -252.2 | 375.5 | 125.0 | |
| Changes by years, y/y, % | -779% | +526% | -445% | -235% | -202% | |||
| Changes by quarters, q/q, % | -298% | -146% | -199% | +50% | -249% | |||